metyrapone has been researched along with Atherogenesis in 1 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| van der Sluis, RJ | 1 |
| van den Aardweg, T | 1 |
| Sijsenaar, TJP | 1 |
| Van Eck, M | 1 |
| Hoekstra, M | 1 |
1 other study available for metyrapone and Atherogenesis
| Article | Year |
|---|---|
Metyrapone Treatment Protects Low-Density Lipoprotein Receptor Knockout Mice against Hypercorticosteronemia Development without Changing Atherosclerosis Susceptibility.
Topics: Animals; Atherosclerosis; Cholesterol; Cholic Acid; Female; Glucocorticoids; Humans; Lipoproteins, L | 2023 |